Zhu et al reported a prognostic score for patients with nonoperable non-small cell lung cancer (NSCLC). This is based on the systemic inflammatory response. The authors are from the Second Affiliated Hospital of Zhejiang University and the Chinese National Ministry of Education in Hangzhou, People's Republic of China.
Patient selection: inoperable non-small-cell lung cancer
Outcome: overall and progression-free survival
Parameters in the week prior to initial chemotherapy:
(1) serum C-reactive protein (CRP) in mg/L
(2) serum LDH in U/L
(3) serum CA125 in U/mL
Parameter |
Finding |
Points |
serum CRP |
<= 20 mg/L |
0 |
|
> 20 mg/L |
1 |
serum LDH |
<= 240 U/L |
0 |
|
> 240 U/L |
1 |
serum CA125 |
<= 70 U/mL |
0 |
|
> 70 U/mL |
1 |
where:
• The analytical methods and reference ranges were not given. All were reported as "elevated".
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 3
• The higher the score the worse the prognosis.
Score |
Median Overall Survival |
Median Progression Free Survival |
0 |
28 months |
10.7 months |
1 |
13 months |
6.1 months |
2 |
11.6 months |
3.6 months |
3 |
8 months |
1.8 months |
Specialty: Hematology Oncology, Surgery, general, Pulmonology